CAMBRIDGE, U.K., Feb. 14, 2005 (PRIMEZONE) -- * Astex, the fragment-based drug discovery and development company, today announced that it has successfully achieved the first milestone in its drug discovery collaboration with Boehringer Ingelheim.
* The multi-target collaboration announced in March 2004 is a three-year alliance for the discovery of novel drugs for various therapeutic indications where Astex is applying its proprietary fragment-based discovery approach, Pyramid(tm).
* Boehringer Ingelheim made an upfront payment to Astex for access to its Pyramid(tm) technology, provides funding for the research programmes and milestone payments and royalties on the sales of approved products.
Full press release attached below: http://hugin.info/132636/R/980349/145269.pdf